Medicine
Truqap 200 mg tablet
Truqap 200 mg tablet is a prescription medicine containing Capivasertib for oral use, marketed by AstraZeneca Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store TRUQAP at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to…
Key facts
- Active ingredient (INN)
- Capivasertib
- Brand
- Truqap
- Strength
- 200 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 64 tablets, 4 blister pack
- Marketing authorisation holder
- AstraZeneca Pharmaceuticals
- Manufacturer
- AstraZeneca Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store TRUQAP at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). Store tablets in the original package.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX27 Capivasertib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 November 2023
- Identifiers
- RxCUI 2669972, 2669978, 2669980 +1DailyMed set ID d698c106-2322-401e-b738-cbd83c843ecfNDC 0310-9501Application NDA218197
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 64 tablet, film coated in 1 bottle | 0310-9501-01 | AstraZeneca Pharmaceuticals | 16 November 2023 |
| 4 blister pack in 1 carton / 16 tablet, film coated in 1 blister pack | 0310-9501-02 | AstraZeneca Pharmaceuticals | 18 October 2024 |
| 4 blister pack in 1 carton / 8 tablet, film coated in 1 blister pack | 0310-9501-04 | AstraZeneca Pharmaceuticals | 3 June 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Capivasertib
Clinical summary
Capivasertib is a prescription medicine indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, among other approved uses. MedsAcross supplies Capivasertib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CapivasertibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TRUQAP prescribing information (AstraZeneca Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Truqap: European public assessment report (EPAR) · European Medicines Agency
Need Truqap 200 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.